BRISTOL-MYERS DISCONTINUING OTC CAPSULE BUSINESS WITH PLANS TO INTRODUCE NEW CAPLET DOSAGES BY JULY; EXCEDRIN TAMPERING FORCES MARKET WITHDRAWAL